GSK

RSV Vaccine Breakthrough: Thousands of Seniors Saved by Game-Changing GSK Shot!

by

Atlanta, Georgia – Respiratory syncytial virus (RSV) poses a significant threat to seniors, leading to numerous hospitalizations and deaths every year. However, recent data from the Centers for Disease Control and Prevention also highlight the severe impact of RSV on adults aged 50 and above, particularly those with underlying chronic conditions such as asthma, diabetes, and congestive heart failure. According to Phil Dormitzer, GSK’s head of vaccines research and development and infectious disease research, approximately …

Read more

Vaccines Battle: Moderna Gears Up for RSV Approval Against Pfizer and GSK – Will They Dominate?

by

Boston, MA – Vaccines have been at the forefront of medical innovation in recent years, with the approval of new shots offering hope for tackling a range of diseases. Moderna, a biotech company based in Boston, Massachusetts, has recently received approval for its shot targeting respiratory syncytial virus (RSV) in older adults. This approval marks a significant step in the company’s efforts to expand its messenger RNA platform beyond just Covid treatments. The Centers for …

Read more